Next generation RNA sequencing elucidates the antitumor effects of Zelnorm via immune microenvironment regulation using DU145 tumor model

Prostate cancer DU145 tumors were subcutaneously established in male nude mice. In nude mice, Zelnorm were orally administrated. Tumor volume and body weight were assessed (tumor volume=1/2 (length×width2)). Tumors were excised and weighted. Tumor samples were profiled by RNA-seq analysis. Respectively, to differentiate the gene expression originated from human (cancer cells) or mouse (tumor TME part), data were mapped against human (GRCh38) and mouse (GRCm38) genomes separately. Overall design: control group (NC), Zelnorm group (MBZ)